NIB and Chr. Hansen continue cooperation in bioscience research

NIB and the Danish bioscience company Chr. Hansen Holding A/S have signed a seven-year loan agreement for research and development (R&D) activities.

The DKK 750 million (approx. EUR 101 million) loan will finance Chr. Hansen’s R&D expenditure during 2021-2023. The investments are aimed at helping Chr. Hansen’s efforts to create and innovate natural sustainable solutions to support the food, beverages, human, animal and plant health industries as well as to speed up large-scale production processes through automation and software development.

Chr. Hansen produces natural ingredient solutions for the food and beverage, health and agriculture industries.

R&D plays a key role in the company’s operations. Around 700 of its employees work in the field, amounting to approximately 19% of the total workforce.

This is NIB’s fifth loan agreement with Chr. Hansen Holding for R&D investments in the last decade.

Founded in 1874, Chr. Hansen Holding A/S is a global supplier of bioscience-based ingredients. The company has around 3,800 employees worldwide.

NIB is an international financial institution owned by eight member countries: Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. The Bank finances private and public projects in and outside the member countries. NIB has the highest possible credit rating, AAA/Aaa, with the leading rating agencies Standard & Poor’s and Moody’s.

For further information, please contact
Vagn Lundhøj, Senior Banker, at +358 10 618 0370, Vagn.Lundhoj@nib.int
Vytautas Brazaitis, Communications Officer, at +358 10 618 0235, vytautas.brazaitis@nib.int